Navigation Links
Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology
Date:6/2/2011

CINCINNATI, June 2, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced the appointment of Robert Shepard, MD, FACP, as Executive Director, Oncology, Medical Affairs effective immediately.  Dr. Shepard is a leading authority on clinical development in oncology, bringing more than four decades of oncology research experience to Kendle. He will oversee the development of oncology programs for customers worldwide, providing medical, safety and scientific support to clinical research teams, investigators and customer contacts.  

"We are delighted Dr. Shepard has joined Kendle," said Melanie A. Bruno, PhD, Vice President, Regulatory and Medical Affairs. "His unsurpassed experience and expertise will be invaluable to our customers as we work with them to bring new oncology therapies to market."  

Dr. Shepard has extensive research credentials in hematology and oncology; is board certified in oncology, hematology and internal medicine; and has a wide array of experience in translational medicine and clinical research. He has been actively involved in oncology research since 1970 and has been responsible for the complete clinical development of several drugs and immune therapies for biopharmaceutical companies, including serving as the consulting Chief Medical Officer for six companies.

Dr. Shepard is a Magna cum Laude graduate of Harvard University in biochemical sciences and molecular biophysics and studied in the Harvard-M.I.T. Health Sciences program.  He earned his medical degree from Duke University in the Medical Scientist Training Program, which included two years of graduate training in immunology.  Dr. Shepard completed a fellowship in hematology and oncology at the Tufts-New England Medical Center where he conducted laboratory research in leukemias, myeloma and myelodysplasia. Dr. Shepard also completed a postdoctoral fellowship in pharmacology and molecular genetics at the Dana-Farber Cancer Center and Harvard Medical School.  He has held academic appointments at Harvard University, Tufts University and the University of Virginia.

To meet Dr. Shepard at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3-7 in Chicago and learn more about Kendle's expertise in oncology clinical development programs, please email info@kendle.com or contact us at +1 800 733 1572.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

For more information, please visit www.kendle.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to Dr. Shepard's anticipated contribution to programs for Kendle customers. Words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "will," "should," "may," and other similar expressions are intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of Kendle's management and involve a number of significant risks and uncertainties, many of which are difficult to predict and are generally beyond the control of Kendle. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional factors that could cause Kendle's results to differ materially from those described in the forward-looking statements can be found in the periodic reports filed with the Securities and Exchange Commission, which are available at the Securities and Exchange Commission's website (http://www.sec.gov) at no charge. Kendle assumes no responsibility to update any forward-looking statements as a result of new information or future developments except as expressly required by law.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
2. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
3. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
4. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
5. Kendle Receives Approval From Indian Government to Proceed With Development of Operations Center in Special Economic Zone
6. Kendle Launches New Global Biostatistics Infrastructure
7. Kendle is First Global CRO to Achieve ISO 9001:2008 Certification in China Through Beijing Affiliate
8. Kendle Executive to Share Insights at World Pharma Trials Asia 2010
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Kendle Advances Early Stage Drug Development with ElMindAs Innovative Brain Network Activation Technology
11. Kendle to Present at 2010 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... 11, 2016 Laboratory glassware and ... laboratories. These may range from microscope slides to large ... made from borosilicate glass because of its low weight ... other hand, started gaining popularity over the past decade ... replace glass with plastic in several applications due to ...
Breaking Medicine Technology:
(Date:2/13/2016)... CA (PRWEB) , ... February 13, 2016 , ... With ... particle overlays to footage all within Final Cut Pro X. Each user can select ... over 3D rotation, angle of view, blur, focus offset, hue, saturation, value, contrast, glow, ...
(Date:2/13/2016)... ... 13, 2016 , ... In the early or “honeymoon” stage of a relationship, ... out of their way to be romantic, and may exaggerate a strength or two ... online dating profile. , A recent study from Queendom.com , however, suggests ...
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... ... , ... As a former television executive, owner Tal Rabinowitz knows how stressful ... decompress, Rabinowitz found herself drawn to a casual meditation class while working at NBC ... implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, she ...
(Date:2/12/2016)... ... ... Every winter, someone is killed, injured or loses a home in an accident ... of the Allegheny Health Network, has partnered with Etna Volunteer Fire Department, and Monroeville ... , “Space Heaters Need Space” aims to bring awareness to the risks ...
Breaking Medicine News(10 mins):